Home›The Library›Atosiban
Atosiban
Atosiban is a real oxytocin-receptor-blocking peptide, approved and widely used to stop preterm labor in the EU, Canada, and dozens of other countries since 2000 — but the FDA has never approved it in the United States, after a US trial found a trend toward more fetal/infant deaths in the atosiban group at the earliest gestational ages studied.
On this page
In brief
Should you care? Only if you're weighing tocolytic (labor-delaying) options during preterm labor — this drug is a real, mainstream option almost everywhere except the United States, for a documented reason worth understanding rather than dismissing.The short version
- A synthetic nonapeptide that blocks oxytocin receptors in the uterus, competitively inhibiting the hormone that drives labor contractions.
- Approved in the EU since 2000 (as Tractocile) and used as a first-line tocolytic in many countries.
- Never FDA-approved — a US trial found a numerical trend toward more fetal/infant deaths in the atosiban arm among the earliest, most extremely premature pregnancies enrolled, a signal the sponsor did not resolve before dropping US development.
An oxytocin-receptor blocker for preterm labor
Atosiban is a synthetic nonapeptide analog of oxytocin, designed to competitively block oxytocin receptors in the uterine muscle. Oxytocin is the hormone that drives labor contractions, so blocking its receptor is a direct, mechanistically clean way to try to delay labor (a "tocolytic") in pregnancies threatened by premature contractions, buying time for interventions like corticosteroids to mature the fetus's lungs before delivery.
Why the FDA never approved it
The pivotal US trial (Romero et al., Am J Obstet Gynecol 2000;182(5):1173-1183, PMID 10819855) randomized 531 patients with preterm labor to intravenous atosiban or placebo, both followed by maintenance dosing of the assigned agent. Among the small subgroup of patients randomized at less than 24 weeks' gestation, fetal/infant deaths were numerically higher in the atosiban group (14 of that subgroup vs. 5 on placebo); at 28 weeks and beyond, outcomes were similar between groups. Because that early-gestation imbalance could not be clearly separated from confounding factors like infection and extreme prematurity, but also could not be ruled out as drug-related, an FDA advisory committee found the safety picture unresolved and did not recommend approval. The drug's sponsor subsequently did not pursue further US development.
The picture outside the US
The European Medicines Agency approved atosiban (as Tractocile) on 20 January 2000, and it remains a first-line or preferred tocolytic in much of Europe, Canada, and elsewhere, generally used in later, more common gestational-age ranges than the small very-early subgroup that drove the US safety signal. Systematic reviews comparing atosiban with other tocolytics (such as nifedipine) generally find broadly similar effectiveness at delaying delivery, with a different side-effect profile rather than a clearly superior or inferior one.
Current status
Marketed as Tractocile (and generic atosiban) across the EU, UK, Canada, and numerous other regulatory jurisdictions. No FDA-approved atosiban product exists, and it has no legal US marketing or compounding pathway — a real, mainstream drug elsewhere, but genuinely unapproved rather than just obscure in the United States.
References
- Romero R, Sibai BM, Sanchez-Ramos L, et al., "An Oxytocin Receptor Antagonist (Atosiban) in the Treatment of Preterm Labor: A Randomized, Double-Blind, Placebo-Controlled Trial with Tocolytic Rescue," Am J Obstet Gynecol 2000;182(5):1173-1183, PMID 10819855.
- European Medicines Agency marketing authorization for Tractocile (atosiban), 20 January 2000.
- FDA Advisory Committee for Reproductive Health Drugs review of atosiban (Antocin) tocolytic application, non-approval.